Position in SYRE
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$30,938,130
+$10,099,200 QoQ
Shares Held
613,365
-3.6% QoQ
Ownership
0.706%
of shares outstanding
% of Portfolio
0.98%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 78%
Shared 0%
None 22%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026EMERALD ADVISERS, LLC holds $427,347,303 across 25 Biotechnology names. SYRE ranks #5 (7.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
1,588,132 | $61,127,200 | |
| 2 | TVTX |
Travere Therapeutics, Inc.
|
1,557,196 | $46,264,293 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
515,361 | $38,270,707 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
397,263 | $36,699,155 | |
| 5 | SYRE |
Spyre Therapeutics, Inc.
This page
|
613,365 | $30,938,130 | |
| 6 | NKTR |
Nektar Therapeutics
|
394,604 | $28,391,757 | |
| 7 | KALV |
KalVista Pharmaceuticals, Inc.
|
1,264,023 | $25,444,782 | |
| 8 | TRVI |
Trevi Therapeutics, Inc.
|
1,839,566 | $21,946,022 |
All Filings in SYRE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,938,130 | 613,365 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $20,838,930 | 636,109 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $9,196,413 | 548,712 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $8,470,969 | 565,863 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $8,839,188 | 547,827 | Shares | Sole | 2025-05-01 | |
| 2024-12-31 | $12,729,294 | 546,791 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $8,604,454 | 292,569 | Shares | Sole | 2024-10-29 | |
| No filing history on record for this holder in this stock. | ||||||